Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Q57412648)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 April 2012

Language	Label	Description	Also known as
English	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	scientific article published on 20 April 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

0 references

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Apostolos Tsapas

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Richard M Bergenstal

2

object named as

R M Bergenstal

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Eleuterio Ferrannini

5

object named as

E Ferrannini

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

10

object named as

D R Matthews

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

S E Inzucchi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M Diamant

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M Nauck

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

R Wender

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

20 April 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

55

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1577-1596

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

https://scigraph.springernature.com/pub.10.1007/s00125-012-2534-0

0 references

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensified glucose control in type 2 diabetes--whose agenda?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Management of type 2 diabetes: summary of updated NICE guidance.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The diabetes mellitus medication choice decision aid: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Patient-important outcomes in registered diabetes trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

N of 1 trials in diabetes: making individual therapeutic decisions

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Translating Comparative Effectiveness Into Practice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The stunned beta cell: a brief history

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Unraveling the science of incretin biology

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Insulin action and substrate competition

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Goals of glycemic control in frail older patients with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Current treatment of non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

We need minimally disruptive medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

A self-regulation program for maintenance of weight loss.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Insulin secretagogues, sulfonylurea receptors and K(ATP) channels

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Incretin-based therapies: review of current clinical trial data.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Three-year efficacy of complex insulin regimens in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The Treat-to-Target Trial and related studies

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The importance of titrating starting insulin regimens in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The relationship between glycemic control and falls in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Associations Between General and Abdominal Adiposity and Mortality in Individuals With Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Monogenic diabetes: implications for therapy of rare types of disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Review article: Thiazolidinediones and heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Contraindications can damage your health--is metformin a case in point?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Use of metformin in the setting of mild-to-moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Epidemiology and natural history of NAFLD and NASH.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Long-term effects of intensive glucose lowering on cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

The combinatorics of medications precludes evidence-based algorithms for therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2534-0

21 January 2018

Severe iatrogenic hypoglycemia in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standards of medical care in diabetes--2011.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22526604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-012-2534-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526604%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57412648&oldid=2089777635"